Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071036 | 0.95 | REN (0.46) | RENCYP3A4TSHRMAPTCHRM1 | |
| SCHEMBL3066403 | 0.94 | REN (0.45) | RENCYP3A4TSHRMAPTCYP1A2 | |
| SCHEMBL3071444 | 0.94 | REN (0.57) | RENCYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL3418842 | 0.94 | REN (0.45) | RENCYP3A4TSHRMAPTCYP1A2 | |
| SCHEMBL3074214 | 0.94 | REN (0.45) | RENCYP3A4TSHRMAPTCYP1A2 | |
| SCHEMBL3083380 | 0.92 | REN (0.43) | RENCYP3A4TSHRMAPTCYP1A2 | |
| SCHEMBL3073347 | 0.92 | REN (0.46) | RENCYP3A4TSHRMAPTDRD2 | |
| SCHEMBL3083569 | 0.92 | REN (0.45) | RENCYP3A4TSHRMAPTCHRM1 | |
| SCHEMBL3087147 | 0.91 | REN (0.43) | RENCYP3A4TSHRMAPTCYP1A2 | |
| SCHEMBL3061053 | 0.91 | REN (0.49) | RENCYP3A4TSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP3A4 29/4885TSHR 3211/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP3A4 29/4885TSHR 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.